Literature DB >> 28839850

Monitoring immunogenicity of protein-based TNF antagonists.

Klaus Bendtzen1, Casper Steenholdt2, Jørn Brynskov2, Ole Ø Thomsen2, Mark A Ainsworth2.   

Abstract

Entities:  

Keywords:  IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; MEDICAL DECISION ANALYSIS

Year:  2015        PMID： 28839850      PMCID： PMC5369473          DOI： 10.1136/flgastro-2015-100596

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


× No keyword cloud information.
  10 in total

Review 1.  Assessing response and loss of response to biological therapies in IBD.

Authors:  Henit Yanai; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2011-03-22       Impact factor: 10.864

Review 2.  Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.

Authors:  Ingrid Ordás; Brian G Feagan; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-17       Impact factor: 11.382

3.  Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.

Authors:  Waqqas Afif; Edward V Loftus; William A Faubion; Sunanda V Kane; David H Bruining; Karen A Hanson; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2010-02-09       Impact factor: 10.864

Review 4.  Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide.

Authors:  Philip Hendy; Ailsa Hart; Peter Irving
Journal:  Frontline Gastroenterol       Date:  2015-01-21

5.  Differential effect of drug interference in immunogenicity assays.

Authors:  Margreet H Hart; Henk de Vrieze; Diana Wouters; Gerrit-Jan Wolbink; Joep Killestein; Els R de Groot; Lucien A Aarden; Theo Rispens
Journal:  J Immunol Methods       Date:  2011-07-29       Impact factor: 2.303

Review 6.  Tailoring treatment to the individual patient: drug monitoring.

Authors:  William J Sandborn
Journal:  Dig Dis       Date:  2014-12-17       Impact factor: 2.404

Review 7.  Therapeutic drug monitoring of biologics for inflammatory bowel disease.

Authors:  Jean-Frédéric Colombel; Brian G Feagan; William J Sandborn; Gert Van Assche; Anne M Robinson
Journal:  Inflamm Bowel Dis       Date:  2011-10-21       Impact factor: 5.325

Review 8.  Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.

Authors:  Klaus Bendtzen; Mark Ainsworth; Casper Steenholdt; Ole Østergaard Thomsen; Jørn Brynskov
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

9.  Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

Authors:  Xavier Roblin; M Rinaudo; E Del Tedesco; J M Phelip; C Genin; L Peyrin-Biroulet; S Paul
Journal:  Am J Gastroenterol       Date:  2014-06-10       Impact factor: 10.864

Review 10.  Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists.

Authors:  Klaus Bendtzen
Journal:  Discov Med       Date:  2013-04       Impact factor: 2.970
  10 in total
  1 in total

Review 1.  Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.

Authors:  Manca Ogrič; Matic Terčelj; Sonja Praprotnik; Matija Tomšič; Borut Božič; Snezna Sodin-Semrl; Saša Čučnik
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.